经历市场的系统性风险下跌之后,业绩高增长带来海利生物的买入良机。海利生物在原有的圆环疫苗和蓝耳疫苗基础上推出口蹄疫、腹泻三联苗两大重磅产品,禽流感等其他新品将陆续推出,正处于业绩爆发性增长的前夜。未来1~2年公司将通过两大重磅产品为主的新品群,换挡进入业绩高速增长的轨道。全球技术领先的口蹄疫苗:海利生物通过合资引进Biogénse BagóS. After experiencing a systemic risk decline in the market, the high growth in performance brought a good opportunity for Haili Bio to buy. Haili Biological launched the original ring vaccine and blue-ear vaccine on the basis of foot-and-mouth disease, triple diarrhea, two heavy products, bird flu and other new products will be introduced one after another, is in the eve of explosive growth in performance. The next 1 to 2 years the company will be based on two major new heavyweight products, shifting into the track of high-performance growth. The world’s leading vaccine for foot and mouth: Haley Biogénse BagóS is introduced through a joint venture.